verapamil has been researched along with Thrombosis in 14 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Thrombosis: Formation and development of a thrombus or blood clot in the blood vessel.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Antithrombotic effects of molsidomine, isosorbide dinitrate and verapamil obtained from the Casela Riedel Pharma GmbH, Frankfurt/Main, Germany have been studied in the laser-induced rat thrombosis model." | 7.68 | [Antithrombotic effects of molsidomine, isosorbide dinitrate and verapamil in a laser-induced thrombosis model]. ( Bielawiec, M; Breddin, H; Krupiński, K, 1993) |
| " In the present study, the effects of two calcium blockers, verapamil and nifedipine, were compared in several rodent thrombosis models." | 7.67 | Comparison of verapamil and nifedipine in thrombosis models. ( Forman, G; Myers, AK; Penhos, J; Ramwell, P; Torres Duarte, AP, 1986) |
| "Antithrombotic effects of molsidomine, isosorbide dinitrate and verapamil obtained from the Casela Riedel Pharma GmbH, Frankfurt/Main, Germany have been studied in the laser-induced rat thrombosis model." | 3.68 | [Antithrombotic effects of molsidomine, isosorbide dinitrate and verapamil in a laser-induced thrombosis model]. ( Bielawiec, M; Breddin, H; Krupiński, K, 1993) |
| "The antithrombotic activity of verapamil (Ver) was assessed in an arterial thrombosis model and an ex vivo thrombosis model." | 3.68 | Antithrombotic activity of verapamil. ( Cui, H; Li, JM; Liao, CL; Yuan, NR; Zou, QJ, 1992) |
| " In the present study, the effects of two calcium blockers, verapamil and nifedipine, were compared in several rodent thrombosis models." | 3.67 | Comparison of verapamil and nifedipine in thrombosis models. ( Forman, G; Myers, AK; Penhos, J; Ramwell, P; Torres Duarte, AP, 1986) |
| " The dihydropyridine agents, CRE-223 and Nifedipine, were highly protective against experimental thrombosis, whereas Verapamil had a weaker and much shorter effect and, on the other hand, Diltiazem had no protective effect over a range of doses." | 3.67 | The antithrombogenic in vivo effects of calcium channel blockers in experimental thrombosis in mice. ( Ortega, MP; Priego, JG; Statkow, PR; Sunkel, C, 1987) |
| "Ex vivo thrombus formation was determined with the use of the Badimon chamber." | 2.76 | Particle traps prevent adverse vascular and prothrombotic effects of diesel engine exhaust inhalation in men. ( Badimon, JJ; Barath, SL; Blomberg, A; Boman, C; Boon, NA; Cassee, FR; Donaldson, K; Gerlofs-Nijland, ME; Langrish, JP; Lucking, AJ; Lundbäck, M; Mills, NL; Newby, DE; Pourazar, J; Sandstrom, T; Sidhu, MK, 2011) |
| " A clopidogrel maintenance dosage of 150 mg daily for 1 week resulted in greater platelet inhibition than 75 mg daily (50 +/- 28% vs." | 2.73 | The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the PRINC (Plavix Response in Coronary Intervention) trial. ( Armstrong, G; Dahl, ML; El-Jack, S; Farrell, H; Gladding, P; Gunes, A; Kay, P; Ormiston, J; Ruygrok, P; Scott, D; Stewart, J; Webster, M; Zeng, I, 2008) |
| "Platelet thrombus formation and whole blood platelet aggregation were measured in 18 stable coronary patients on three separate occasions: at baseline when receiving no active medications, after 7 days of receiving oral verapamil SR (240 mg/d), and after 7 days of receiving a combination of oral verapamil SR and aspirin (325 mg/d)." | 1.29 | Oral verapamil inhibits platelet thrombus formation in humans. ( Hung, J; L-Lacoste, L; Lam, JY; Waters, D, 1994) |
| "When the mural thrombus was removed from 14 grafts, a median 73% of the platelets were located in the interface between thrombus and graft." | 1.27 | Comparison of the antithrombotic action of calcium antagonist drugs with dipyridamole in dogs. ( Chesebro, JH; Dewanjee, MK; Fuster, V; Kaye, MP; Pumphrey, CW; Vlietstra, RE, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (50.00) | 18.7374 |
| 1990's | 5 (35.71) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 1 (7.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gladding, P | 1 |
| Webster, M | 1 |
| Zeng, I | 1 |
| Farrell, H | 1 |
| Stewart, J | 1 |
| Ruygrok, P | 1 |
| Ormiston, J | 1 |
| El-Jack, S | 1 |
| Armstrong, G | 1 |
| Kay, P | 1 |
| Scott, D | 1 |
| Gunes, A | 1 |
| Dahl, ML | 1 |
| Lucking, AJ | 1 |
| Lundbäck, M | 1 |
| Barath, SL | 1 |
| Mills, NL | 1 |
| Sidhu, MK | 1 |
| Langrish, JP | 1 |
| Boon, NA | 1 |
| Pourazar, J | 1 |
| Badimon, JJ | 1 |
| Gerlofs-Nijland, ME | 1 |
| Cassee, FR | 1 |
| Boman, C | 1 |
| Donaldson, K | 1 |
| Sandstrom, T | 1 |
| Newby, DE | 1 |
| Blomberg, A | 1 |
| Pumphrey, CW | 2 |
| Fuster, V | 2 |
| Dewanjee, MK | 2 |
| Chesebro, JH | 1 |
| Vlietstra, RE | 2 |
| Kaye, MP | 2 |
| Murphy, KP | 1 |
| Krupiński, K | 1 |
| Breddin, H | 1 |
| Bielawiec, M | 1 |
| L-Lacoste, L | 1 |
| Lam, JY | 1 |
| Hung, J | 1 |
| Waters, D | 1 |
| Beaughard, M | 1 |
| Brasset, M | 1 |
| John, G | 1 |
| Massingham, R | 1 |
| Ceceña, FA | 1 |
| Hoelzinger, DH | 1 |
| Liao, CL | 1 |
| Zou, QJ | 1 |
| Li, JM | 1 |
| Cui, H | 1 |
| Yuan, NR | 1 |
| LeVeen, RF | 1 |
| Wolf, GL | 1 |
| Biery, D | 1 |
| Myers, AK | 1 |
| Forman, G | 1 |
| Torres Duarte, AP | 1 |
| Penhos, J | 1 |
| Ramwell, P | 1 |
| Jy, W | 1 |
| Ahn, YS | 1 |
| Shanbaky, N | 1 |
| Fernandez, LF | 1 |
| Harrington, WJ | 1 |
| Haynes, DH | 1 |
| Ortega, MP | 1 |
| Sunkel, C | 1 |
| Priego, JG | 1 |
| Statkow, PR | 1 |
| Nissen, P | 1 |
| Alexander, K | 1 |
| Nedden, KH | 1 |
| Fabel, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Modifying Anti-platelet Treatment to Ticagrelor in Patients With Diabetes and Low Response to Clopidogrel[NCT01643031] | Phase 4 | 500 participants (Anticipated) | Interventional | 2012-08-31 | Not yet recruiting | ||
| The Effect of a Retrofit Particle Trap on the Vascular Effects of Diesel Exhaust Inhalation[NCT00745446] | 18 participants (Actual) | Interventional | 2007-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for verapamil and Thrombosis
| Article | Year |
|---|---|
The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the PRINC (Plavix Response in Coronary Intervention) trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Calcium Channel Blockers; Clopidogrel; D | 2008 |
Particle traps prevent adverse vascular and prothrombotic effects of diesel engine exhaust inhalation in men.
Topics: Acetylcholine; Adult; Air Pollutants; Automobiles; Bradykinin; Cross-Over Studies; Endothelium, Vasc | 2011 |
12 other studies available for verapamil and Thrombosis
| Article | Year |
|---|---|
Comparison of the antithrombotic action of calcium antagonist drugs with dipyridamole in dogs.
Topics: Animals; Blood Platelets; Calcium Channel Blockers; Dipyridamole; Disease Models, Animal; Dogs; Fibr | 1983 |
A new in vivo model of arterial thrombosis: the effect of administration of ticlopidine and verapamil in dogs.
Topics: Administration, Oral; Animals; Disease Models, Animal; Dogs; Drug Evaluation, Preclinical; Femoral A | 1982 |
[Antithrombotic effects of molsidomine, isosorbide dinitrate and verapamil in a laser-induced thrombosis model].
Topics: Animals; Dose-Response Relationship, Drug; Isosorbide Dinitrate; Lasers; Male; Mesenteric Arteries; | 1993 |
Oral verapamil inhibits platelet thrombus formation in humans.
Topics: Administration, Oral; Adult; Aged; Angina Pectoris; Aspirin; Blood Platelets; Blood Pressure; Delaye | 1994 |
Failure of calcium channel blockade to reduce platelet-mediated cyclic flow variations in dogs with coronary stenosis and endothelial injury.
Topics: Animals; Aspirin; Calcium Channel Blockers; Coronary Circulation; Coronary Disease; Diltiazem; Disea | 1995 |
Transcatheter therapy of thrombotic-occlusive lesions in saphenous vein grafts.
Topics: Aged; Combined Modality Therapy; Coronary Angiography; Coronary Artery Bypass; Disease-Free Survival | 1996 |
Antithrombotic activity of verapamil.
Topics: Animals; Blood Viscosity; Female; Male; Rabbits; Rats; Thrombosis; Verapamil | 1992 |
Angioplasty-induced vasospasm in rabbit model. Mechanisms and treatment.
Topics: Angioplasty, Balloon; Animals; Extravasation of Diagnostic and Therapeutic Materials; Femoral Artery | 1985 |
Comparison of verapamil and nifedipine in thrombosis models.
Topics: Animals; Arachidonic Acid; Arachidonic Acids; Collagen; Disease Models, Animal; Epinephrine; Male; N | 1986 |
Abnormal calcium handling by platelets in thrombotic disorders.
Topics: Blood Platelets; Calcium; Humans; Organoids; Osmolar Concentration; Platelet Aggregation; Rest; Thro | 1987 |
The antithrombogenic in vivo effects of calcium channel blockers in experimental thrombosis in mice.
Topics: Animals; Calcium Channel Blockers; Collagen; Dihydropyridines; Diltiazem; Disease Models, Animal; Do | 1987 |
[Drug therapy of chronic arterial occlusion of the extremities by intraarterial administration of Verapramil].
Topics: Adult; Aged; Blood Pressure; Chronic Disease; Electrocardiography; Femoral Artery; Heart Rate; Human | 1972 |